Computer SoftwareĪ measure of selectivity of effect representing the ratio of the median-effect dose for toxicity in relation to the dose of the therapeutic effect. The estimated dose required to produce the given effect is displayed for a range of effect values. The combined effect predicted by the mass-action law principle. CalcuSyn 40 You will then be able to see the tables and fields present in the source and select those to import.Ĭalusyn the Program 23 Step 5 – Click the Finish button and the drug will be added to the experiment and shown in the Contents Pane. You can only enter non-constant ratio combinations containing up to 6 drugs using the wizard. A general equation for dose-effect relationship derived by Chou 2 through mathematical induction using hundreds of enzyme kinetic models. Raw Data You can export raw data as tab separated text. Once you have entered mnaual correct password, you will be able to run CalcuSyn repeatedly. Quantitative dose-effect analysis and algorithms: Data should be in the form of a tab separated. CalcuSyn for Windows, Multiple-drug dose-effect analyzer and manual.
Calcusyn software free manual#
Manual and Software, Biosoft, Cambridge, U.K., Chou, T.-C. and antagonism, respectively (Source: CalcuSyn manual, Biosoft, ).
Calcusyn software free software#
combination-index data generated by CalcuSyn software analyses. Gemcitabine exhibits biologic activity against canine OSA cell lines, and carboplatin combined with gemcitabine exhibits synergistic activity at biologically relevant concentrations.年1月23日 CalcuSyn is a software tool whose main purpose is to aid individuals in analyzing mixed drug treatments, a more and more used practice in. No grade 3 or 4 hematologic or gastrointestinal toxicities were noted in the patients for which data was available however, one death was attributed to chemotherapy toxicity.
Calcusyn software free free#
In the clinical study, the median follow-up time from diagnosis was 171 days, and 38 of the 45 dogs were still alive at the time of writing therefore, disease free interval and median survival time could not be calculated. This activity was greater when cells were treated with carboplatin prior to gemcitabine, versus gemcitabine prior to carboplatin in 3 of 4 OSA cell lines. However, when OSA cell lines were treated with gemcitabine and carboplatin in combination, a significant decrease in cell viability was observed compared to gemcitabine alone, and the drug combination was synergistic. No synergistic or additive activity was noted when canine OSA cell lines were treated with gemcitabine and pamidronate. In the preclinical study, treatment of canine OSA cell lines with gemcitabine induced growth inhibition, cell cycle arrest, and apoptosis. Dogs were monitored for metastatic disease during the treatment course and every three months after the completion of chemotherapy. Each dog received carboplatin 300mg/m2 and gemcitabine 2mg/kg following amputation for four treatment cycles. Following the preclinical study, forty-five dogs with stage II appendicular OSA were enrolled into a multicenter, prospective clinical trial. Synergy was quantified by combination index (CI) analysis using Calcusyn software. Loss of cell viability was assessed using the water soluble tetrazolium-1 (WST-1) assay, cell cycle analysis was evaluated using propidium iodide staining, and apoptosis was assessed by measuring caspase-3/7 activation. OSA cell lines OSA8, OSA16, OSA32, and OSA36 were treated with gemcitabine alone or in combination with pamidronate or carboplatin. Additionally, we predicted that the toxicity of the gemcitabine and carboplatin combination would be comparable to carboplatin alone in dogs with OSA post-amputation. We hypothesized that gemcitabine in combination with carboplatin would significantly improve 1-year survival rates in dogs with OSA following amputation compared to carboplatin alone.
Subsequent to the in vitro study, we evaluated whether gemcitabine administered in combination with carboplatin would improve outcome in dogs with OSA. The purpose of this study was to evaluate the activity of gemcitabine against canine OSA cell lines alone or in combination with compounds known to have activity against OSA in vitro, including the bisphosphonate pamidronate and the chemotherapeutic carboplatin. Gemcitabine, an analog of cytosine arabinoside, inhibits the growth of human osteosarcoma (OSA) cell lines in vitro as well as in mouse xenograft models.